×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMY – bristol-myers squibb company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
9/22
06:59 am
bmy
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
Low
Report
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
9/20
06:59 am
bmy
Bristol Myers Squibb Announces Dividend
Low
Report
Bristol Myers Squibb Announces Dividend
9/18
03:09 pm
bmy
AARP weighs in on Merck case challenging Medicare drug negotiation [Seeking Alpha]
Low
Report
AARP weighs in on Merck case challenging Medicare drug negotiation [Seeking Alpha]
9/18
01:32 pm
bmy
Cytokinetics: Clinical Efficacy Isn't Enough For Success [Seeking Alpha]
Low
Report
Cytokinetics: Clinical Efficacy Isn't Enough For Success [Seeking Alpha]
9/17
07:57 pm
bmy
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
Low
Report
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
9/15
09:40 pm
bmy
Bristol Myers Squibb: Pharma And Government Playing 'Chicken' Over New Drug Pricing Rules [Seeking Alpha]
Low
Report
Bristol Myers Squibb: Pharma And Government Playing 'Chicken' Over New Drug Pricing Rules [Seeking Alpha]
9/15
06:49 pm
bmy
bluebird bio And 2seventy bio - Spinner And Spun: The Better Bet In Cell Therapy [Seeking Alpha]
Low
Report
bluebird bio And 2seventy bio - Spinner And Spun: The Better Bet In Cell Therapy [Seeking Alpha]
9/15
06:34 pm
bmy
US Chamber of Commerce urges judge to block Medicare drug pricing program [Reuters]
Low
Report
US Chamber of Commerce urges judge to block Medicare drug pricing program [Reuters]
Date
Time
Symbol
Company Name
Action
%Chg
7/27/2023
06:59 am
bmy
bristol-myers squibb company
MISS
Report
-4.8%
bristol-myers squibb company
4/27/2023
06:59 am
bmy
bristol-myers squibb company
BEAT
Report
-1.1%
bristol-myers squibb company
2/2/2023
06:59 am
bmy
bristol-myers squibb company
BEAT
Report
0.9%
bristol-myers squibb company
10/25/2022
07:31 pm
bmy
bristol-myers squibb company
BEAT
Report
2.3%
bristol-myers squibb company
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
8/28
05:29 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Aug 24 Filed by: Powell Ann
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Aug 24 Filed by: Powell Ann
8/24
02:18 pm
bmy
Form 144 BRISTOL MYERS SQUIBB CO Filed by: Powell Ann
Low
Report
Form 144 BRISTOL MYERS SQUIBB CO Filed by: Powell Ann
8/10
07:10 am
bmy
Form 8-K BRISTOL MYERS SQUIBB CO For: Aug 09
Low
Report
Form 8-K BRISTOL MYERS SQUIBB CO For: Aug 09
8/7
05:24 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Aug 03 Filed by: Plenge Robert M
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Aug 03 Filed by: Plenge Robert M
8/3
03:55 pm
bmy
Form 144 BRISTOL MYERS SQUIBB CO Filed by: Plenge Robert M
Low
Report
Form 144 BRISTOL MYERS SQUIBB CO Filed by: Plenge Robert M
7/27
12:29 pm
bmy
Form 10-Q BRISTOL MYERS SQUIBB CO For: Jun 30
Low
Report
Form 10-Q BRISTOL MYERS SQUIBB CO For: Jun 30
7/27
07:51 am
bmy
Form 8-K BRISTOL MYERS SQUIBB CO For: Jul 27
Low
Report
Form 8-K BRISTOL MYERS SQUIBB CO For: Jul 27
7/5
09:34 pm
bmy
Form 3 BRISTOL MYERS SQUIBB CO For: Jul 03 Filed by: Plenge Robert M
Low
Report
Form 3 BRISTOL MYERS SQUIBB CO For: Jul 03 Filed by: Plenge Robert M
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/24
Bristol-Myers releases mixed Opdivo lung cancer results [Reuters]
10.2%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
TOP News Decliners
6/24
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
-7.8%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: